Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Bluebird bio Inc    BLUE

BLUEBIRD BIO INC (BLUE)
Mes dernières consult.
Most popular
Report
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

bluebird bio, Inc. (NASDAQ:BLUE) Files An 8-K Entry into a Material Definitive Agreement

share with twitter share with LinkedIn share with facebook
share via e-mail
0
09/28/2017 | 10:17pm CET

bluebird bio, Inc. (NASDAQ:BLUE) Files An 8-K Entry into a Material Definitive AgreementItem 1.01Entry into a Materials Definitive Agreement

On September 22, 2017, Celgene Corporation (“Celgene”) exercised its option to exclusively license bb21217 (“bb21217”), the second anti-BCMA product candidate under the Amended and Restated Collaboration Agreement dated June 3, 2015 (as amended, the “Amended Collaboration Agreement”) between Celgene and bluebird bio, Inc. (“bluebird”). In connection with its option exercise, Celgene will pay to bluebird an option exercise payment of $15.0 million in accordance with the terms of the Amended Collaboration Agreement. On September 28, 2017, the parties entered into the Amended and Restated License Agreement (the “License Agreement”), which provides for, among other matters, Celgene’s exclusive worldwide license to develop and commercialize bb21217. Under the License Agreement, subject to customary “back-up” supply rights granted to Celgene, bluebird has the sole right to manufacture or have manufactured supplies of vectors and associated payloads manufactured for incorporation into bb21217. Celgene will reimburse bluebird for its costs to manufacture and supply such vectors and associated payloads, plus a modest mark-up. bluebird will continue to be responsible for conducting the ongoing CRB-402 Phase 1 clinical study of bb21217 for the treatment of relapsed/refractory multiple myeloma. Following the completion of the CRB-402 Phase 1 clinical study, Celgene will be responsible for all costs and expenses for the development and commercialization of bb21217, subject to bluebird’s co-development and co-promotion option described below.

bluebird may elect to co-develop and co-promote bb21217 in the United States. If bluebird does not exercise its option to co-develop and co-promote bb21217 in the United States, bluebird will be eligible to receive up to $10.0 million in clinical milestone payments, up to $117.0 million in regulatory milestone payments and up to $78.0 million in commercial milestone payments, in addition to the option fee. bluebird will also be eligible to receive a percentage of net sales as a royalty in a range from the mid-single digits to low-teens. The royalties payable to bluebird are subject to certain reductions, including for any royalty payments required to be made by Celgene to acquire patent rights, with an aggregate minimum floor.

If bluebird elects to co-develop and co-promote bb21217 in the United States, then bluebird and Celgene would share equally in all costs incurred relating to the development, commercialization and manufacture of bb21271 within the United States and share equally in the profits generated by bb21217 in the United States. Additionally, if bluebird elects to co-develop and co-promote bb21217, then the milestones and royalties would decrease compared to those described above. Under this scenario, bluebird would receive up to $10.0 million in clinical milestone payments and outside of the United States, up to $54.0 million in regulatory milestone payments and up to $36.0 million in commercial milestone payments, in addition to the option fee. Furthermore, to the extent any of the product candidates licensed by Celgene and co-developed and co-promoted by bluebird are commercialized, bluebird would be entitled to receive tiered royalty payments ranging from the mid-single digits to low-teens based on a percentage of net sales form sales generated outside of the United States. The royalties payable to bluebird are subject to certain reductions, including for any royalty payments required to be made by Celgene to acquire patent rights, with an aggregate minimum floor. Celgene will assume certain development obligations and must report on their progress in achieving these milestones on a quarterly basis.

Absent early termination, the License Agreement will continue on a country-by-country basis, until there are no more payments owed to bluebird on bb21217 in such country. Celgene has the right to terminate the License Agreement at its discretion upon 180-day notice, beginning with the 18-month anniversary of the effective date of the License Agreement. Each party may also terminate the License Agreement upon prior notice for an uncured material breach that fundamentally frustrates the transactions contemplated by the License Agreement. bluebird also has the right to terminate the License Agreement if Celgene or any of its affiliates challenges the validity, scope or enforceability of or otherwise opposes, any patent included within the intellectual property rights licensed to Celgene under the License Agreement.

On September 28, 2017, the parties further amended the Amended Collaboration Agreement. The amendment provides for, among other matters, updated timing for certain deliverables in connection with Celgene’s option to exclusively license bb21217.

The foregoing descriptions oftheLicense Agreementand theamendment to theAmended CollaborationAgreementdo not purport to be a complete statement of the parties’ rights under such agreements and are qualified in their entirety by reference to the full text of such agreements, a copy of each such agreement will be filed as an exhibit to bluebird’squarterly report on Form 10-Q for the quarter ended September 30, 2017.

Item 8.01Other Events

On September 28, 2017, bluebird bio, Inc. (“bluebird”) issued a press release announcing the treatment of the first subject in the CRB-402 Phase I clinical study of bb21217 for the treatment of relapsed/refractory multiple myeloma.The full text of the press release regarding the announcement is filed as exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

Item 9.01Financial Statements and Exhibits.

(d) Exhibits

bluebird bio, Inc. ExhibitEX-99.1 2 blue-ex991_6.htm EX-99.1 blue-ex991_6.htm     Exhibit 99.1   bluebird bio Announces First Patient Treated with Second Anti-BCMA CAR T bb21217 in CRB-402 Phase 1 Study in Patients with Relapsed/Refractory Multiple Myeloma   -Celgene has exercised its option to exclusively license bb21217 under its collaboration with bluebird bio- -bluebird bio to receive $15 million option exercise payment from Celgene-   Cambridge,…To view the full exhibit click here
About bluebird bio, Inc. (NASDAQ:BLUE)
bluebird bio, Inc. is a biotechnology company. The Company is focused on developing transformative gene therapies for severe genetic and rare diseases and in the field of T cell-based immunotherapy. Its gene therapy clinical programs include LentiGlobin product candidate to treat transfusion-dependent B-thalassemia (TDT) and severe sickle cell disease (SCD), and Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD), a rare hereditary neurological disorder. Its oncology programs are built using lentiviral gene delivery and T cell engineering, with a focus on developing T cell-based immunotherapies, including chimeric antigen receptor (CAR) and T cell receptor (TCR) T cell therapies. Its oncology program, bb2121, is a CAR T cell product candidate targeting B-cell maturation antigen, or BCMA, in multiple myeloma. It also offers discovery research programs utilizing megaTALs/homing endonuclease gene editing technologies for use across its pipeline.

The post bluebird bio, Inc. (NASDAQ:BLUE) Files An 8-K Entry into a Material Definitive Agreement appeared first on Market Exclusive.

© Market Exclusive 2017, source Market Exclusive

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on BLUEBIRD BIO INC
09:19a BLUEBIRD BIO : Stock Soars on Unprecedented Blood Cancer Study Results
12/11 Apple and Chesapeake Energy rise; Spark Therapeutics sinks
12/11 BLUEBIRD BIO : Announces Proposed Public Offering of Common Stock
12/11 BLUEBIRD BIO : Presents Updated Data from HGB-205 Study of LentiGlobinTM Gene Th..
12/11 BLUEBIRD BIO, INC. : Other Events, Financial Statements and Exhibits (form 8-K)
12/11 BLUEBIRD BIO : Presents Updated Data from HGB-205 Study of LentiGlobinTM Gene Th..
12/10 BLUEBIRD BIO : Announces Updated Clinical Results from Ongoing Phase 1 Multicent..
12/10 BLUEBIRD BIO : Presents New Data from Clinical Studies of LentiGlobin™ Gen..
12/10 BLUEBIRD BIO : Celgene Corporation and bluebird bio Announce Updated Results fro..
12/10 CELGENE CORPORATION : and bluebird bio Announce Updated Results from Ongoing Mul..
More news
News from SeekingAlpha
12:19a BIOTECH ANALYSIS CENTRAL PHARMA NEWS : Bluebird Bio's Success, Spark's Hemophili..
12/11 Bluebird bio readies equity offering
12/11 Midday Gainers / Losers
12/11 bluebird bio (BLUE) Investor Presentation - Slideshow
12/11 HEALTHCARE - TOP 5 GAINERS / LOSERS : 05 am
Financials ($)
Sales 2017 38,9 M
EBIT 2017 -292 M
Net income 2017 -298 M
Finance 2017 731 M
Yield 2017 -
P/E ratio 2017 -
P/E ratio 2018
EV / Sales 2017 219x
EV / Sales 2018 324x
Capitalization 9 249 M
Chart BLUEBIRD BIO INC
Duration : Period :
bluebird bio Inc Technical Analysis Chart | BLUE | US09609G1004 | 4-Traders
Technical analysis trends BLUEBIRD BIO INC
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 17
Average target price 167 $
Spread / Average Target -17%
EPS Revisions
Managers
NameTitle
Nick Leschly President, Chief Executive Officer & Director
Daniel S. Lynch Chairman
Susanna G. High Chief Operating Officer
Jeffrey T. Walsh CAO, Chief Financial & Strategy Officer
David M. Davidson Chief Medical Officer
Sector and Competitors
1st jan.Capitalization (M$)
BLUEBIRD BIO INC172.12%9 249
GILEAD SCIENCES1.55%99 094
REGENERON PHARMACEUTICALS1.78%40 969
VERTEX PHARMACEUTICALS88.38%35 831
GENMAB1.79%11 452
EXELIXIS, INC.80.42%7 816